Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by MustangSalleyon Apr 08, 2021 12:00pm
162 Views
Post# 32956949

RE:RE:Presentation

RE:RE:Presentation

Markhamjohn wrote: Could be Bio Tech. He seems to have a lot of shares and said the following recently. "I sell at 1.60 and above and I have been for a while now. That isn't a secret. Remember my cost on these shares is literally next to nil so even at 40 cents,..."


There are some large investors that hold massive positions ... that are unhappy with management . Management has just given them lip service while they were so loyal. As one poster said recently , most of these investors are now really looking at the reality if Tolekis and the board can take this to the next level.  There are lots of headwinds and no vision by msnagement.

Dont get me wrong I would live to see Sernova become a leader and be worth mulitbilliions but i believe Dr Toleikis and bod have taken this far as they can . They have no capital market experience and no ability to execute in the commercial side. Yes on the scientific side have made great progress.

it's not Bioteck alone selling imo. Also you will have another 20 million warrants from this lousy deal which Tolekis has not explained what the funds are for. And u have two sets of warrants expiring in 2022 which will hold so down .

The fact Toleikis cannot get a major pharma as a collaborator is key for success. Without a major partnership with a pharma that can put in $100 million for clinical trials to get Fda approval , Sva will go nowhere . This money will be gone within 1.5 years . The inability for Tolekis to negioate a poor dilutive financing deal does not leave much hope in his business skills in negiotating a pharma deal imo. 

I could be wrong but look at his recent lack of actions since the financing how many months ago? Where is the polymer coating data that the company bought ? Why are you paying a Ray Matthews Abx doing used car salesman pr's like Troy media? Why were you in such a rush to extend warrants and do a poor deal ? It's been several months now and you can't explain yourself ?

So I feel bad for all thiose investors that bought above $1.60 because investors that bought at much lower prices are mulling whether to exit here or not . The problem is that there is not enough liquidity to get out and for all the reasons listed above the sp will be hard to get over $3 in my opinion.

Announce the AGM and allow shareholders to cite fairly and I will stop posting Phil because you spend more time reading the blogs than doing any real work.

Ms Sally 
 

<< Previous
Bullboard Posts
Next >>